DiaMedica Therapeutics Inc. - 8-K Filing
DiaMedica Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders on May 20, 2026, where shareholders voted on four proposals: re-electing seven directors with majority support for each nominee; ratifying Baker Tilly US, LLP as the independent registered public accounting firm (approved by a vote of 20,950,404 to 578,926); approving executive compensation advisory (9,928,381 votes in favor); and amending its 2019 Omnibus Incentive Plan to add 3.5 million shares (approved by a vote of 9,693,413). (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $DMAC